专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080207512A1 Methods for Treating Obesity and Obesity Related and Disorders 失效
标题翻译：治疗肥胖和肥胖相关和疾病的方法
公开(公告)号：US20080207512A1
公开(公告)日：2008-08-28
申请号：US11940317
申请日：2007-11-14
申请人： Jonathan D. Roth , Christen M. Anderson , Alain D. Baron
发明人： Jonathan D. Roth , Christen M. Anderson , Alain D. Baron
IPC分类号： A61K38/16 , A61P3/04
CPC分类号： A61K38/22 , A61K31/135 , A61K31/454 , A61K31/7048 , A61K38/2264 , A61K38/2278 , A61K2300/00
摘要： Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
摘要翻译：公开了治疗肥胖或肥胖相关疾病的方法。这些方法包括使用针对前脑的抗肥胖剂与针对后脑的抗肥胖剂的组合。

2. 发明授权

US08999970B2 Administration of an anti-obesity compound to individuals with renal impairment 有权
标题翻译：向患有肾损伤的个体施用抗肥胖化合物
公开(公告)号：US08999970B2
公开(公告)日：2015-04-07
申请号：US13511639
申请日：2011-08-31
申请人： Christen M. Anderson , William R. Shanahan
发明人： Christen M. Anderson , William R. Shanahan
IPC分类号： A61K31/55 , G01N33/70
CPC分类号： A61K31/55 , A61K9/0053 , G01N33/70 , Y10T436/147777
摘要： The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.
摘要翻译：本公开内容涉及通过确定个体的肾功能水平并开出或施用治疗有效量的（R）-8-氯-1-甲基-2,3， 4,5-四氢-1H-3-苯并吖庚因或其药学上可接受的盐，溶剂化物或水合物，条件是个体具有选自以下的肾功能水平：无肾损伤，轻度肾损伤，和中度肾损伤。此外，本公开涉及用（R）-8-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并氮杂或其药学上可接受的盐，溶剂化物或水合物从多个需要体重管理的个体中确定个体的肾功能水平，并选择个体用（R）-8-氯-1-甲基-2,3,4,5-四氢 - 四氢-1H-3-苯并吖庚因或其药学上可接受的盐，溶剂化物或水合物，如果个体具有选自以下的肾功能水平：无肾损伤，轻度肾损伤和中度肾损伤。

3. 发明授权

US08394765B2 Methods of treating obesity with two different anti-obesity agents 失效
标题翻译：用两种不同的抗肥胖剂治疗肥胖症的方法
公开(公告)号：US08394765B2
公开(公告)日：2013-03-12
申请号：US11940317
申请日：2007-11-14
申请人： Jonathan D. Roth , Christen M. Anderson , Alain D. Baron
发明人： Jonathan D. Roth , Christen M. Anderson , Alain D. Baron
IPC分类号： A61K38/00 , A61K38/16 , A61K38/22
CPC分类号： A61K38/22 , A61K31/135 , A61K31/454 , A61K31/7048 , A61K38/2264 , A61K38/2278 , A61K2300/00
摘要： Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
摘要翻译：公开了治疗肥胖或肥胖相关疾病的方法。这些方法包括使用针对前脑的抗肥胖剂与针对后脑的抗肥胖剂的组合。

4. 发明申请

US20130267500A1 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL 审中-公开
标题翻译： 5-HT2C受体拮抗剂通过降低肾上腺素水平来治疗疾病
公开(公告)号：US20130267500A1
公开(公告)日：2013-10-10
申请号：US13820073
申请日：2011-08-31
申请人： Christen M. Anderson , William R. Shanahan
发明人： Christen M. Anderson , William R. Shanahan
IPC分类号： A61K31/55
CPC分类号： A61K31/55 , A61K31/00
摘要： Uses of 5-HT2C receptor agonists in the treatment of disorders ameliorated by reduction of an individual's norepinephrine level, wherein said disorders include but are not limited to hypernorepinephrinemia, cardiomyopathy, cardiac hypertrophy, cardiomyocyte hypertrophy in post-myocardial infarction remodeling, elevated heart rate, vasoconstriction, acute pulmonary vasoconstriction, hypertension, heart failure, cardiac dysfunction after stroke, cardiac arrhythmia, metabolic syndrome, abnormal lipid metabolism, hyperthermia, Cushing syndrome, pheochromocytoma, epilepsy, obstructive sleep apnea, insomnia, glaucoma, osteoarthritis, rheumatoid arthritis, and asthma.
摘要翻译： 5-HT 2C受体激动剂在治疗通过减少个体去甲肾上腺素水平而改善的病症中的用途，其中所述疾病包括但不限于高肾上腺素肾血症，心肌病，心脏肥大，心肌梗塞后心肌重塑中的心肌细胞肥大，心率升高，血管收缩，急性肺血管收缩，高血压，心力衰竭，卒中后心脏功能障碍，心律失常，代谢综合征，脂代谢异常，高热，库兴综合征，嗜铬细胞瘤，癫痫，阻塞性睡眠呼吸暂停，失眠，青光眼，骨关节炎，类风湿性关节炎和哮喘。

5. 发明授权

US06906174B2 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor 失效
公开(公告)号：US06906174B2
公开(公告)日：2005-06-14
申请号：US09809827
申请日：2001-03-16
申请人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley
发明人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley
IPC分类号： G01N33/50 , A61K31/704 , A61K31/7048 , A61K31/7056 , A61K31/7064 , A61K45/00 , A61P3/00 , A61P3/10 , A61P17/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/16 , A61P35/00 , A61P43/00 , C07H15/256 , C07H15/26 , C07K1/22 , C07K14/47 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/62 , C12P21/02 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566 , C07K1/00 , C07K14/00
CPC分类号： C07K14/47 , C07K2319/00 , C07K2319/07 , C07K2319/21 , C07K2319/23 , C12N15/62 , C12N2799/021
摘要： Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

6. 发明授权

US06906173B2 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor 失效
公开(公告)号：US06906173B2
公开(公告)日：2005-06-14
申请号：US09185904
申请日：1998-11-03
申请人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley
发明人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley
IPC分类号： C07K14/47 , C12N5/02 , C12N15/62 , C07K1/00 , C07K14/00
CPC分类号： C12N15/62 , C07K14/47 , C07K2319/00 , C07K2319/07 , C07K2319/21 , C07K2319/23 , C12N2799/021
摘要： Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

7. 发明授权

US06653094B2 Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus 失效
公开(公告)号：US06653094B2
公开(公告)日：2003-11-25
申请号：US09924313
申请日：2001-08-07
申请人： Christen M. Anderson , Robert E. Davis
发明人： Christen M. Anderson , Robert E. Davis
IPC分类号： C12Q132
CPC分类号： C12Q1/6883 , G01N33/6893 , G01N2800/042
摘要： The present invention relates to improved diagnostic methods for early detection of a risk for developing type 2 diabetes mellitus in humans, and screening assays for therapeutic agents useful in the treatment of type 2 diabetes mellitus, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.

8. 发明授权

US06280966B1 Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus 失效
标题翻译：线粒体功能改变的指标，用于确定2型糖尿病风险的预测方法
公开(公告)号：US06280966B1
公开(公告)日：2001-08-28
申请号：US09521407
申请日：2000-03-08
申请人： Christen M. Anderson , Robert E. Davis
发明人： Christen M. Anderson , Robert E. Davis
IPC分类号： C12Q132
CPC分类号： C12Q1/6883 , G01N33/6893 , G01N2800/042
摘要： The present invention relates to improved diagnostic methods for early detection of a risk for developing type 2 diabetes mellitus in humans, and screening assays for therapeutic agents useful in the treatment of type 2 diabetes mellitus, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, celullar responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.
摘要翻译：本发明涉及用于早期检测人类发展中的2型糖尿病的风险的改进的诊断方法，以及用于治疗2型糖尿病的治疗药物的筛选测定法，通过比较一种或多种改变的线粒体功能。改变线粒体功能的指标包括线粒体酶和ATP生物合成因子等酶。线粒体功能改变的其他指标包括线粒体质量，线粒体数量和线粒体DNA含量，细胞内钙升高和凋亡细胞的纤溶酶反应以及自由基生成。还提供了用于治疗和分层人类患者的方法，这些方法涉及公开的改变的脑膜功能指标。

9. 发明授权

US07001729B2 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor 失效
公开(公告)号：US07001729B2
公开(公告)日：2006-02-21
申请号：US09811131
申请日：2001-03-14
申请人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley , Scott W. Miller , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
发明人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley , Scott W. Miller , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
IPC分类号： G01N29/00 , G01N33/573 , C12N11/00
CPC分类号： C07K14/47 , C07K2319/00 , C07K2319/07 , C07K2319/21 , C07K2319/23 , C12N15/62 , C12N2799/021
摘要： Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

10. 发明授权

US06906175B2 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor. 失效
标题翻译：腺嘌呤核苷酸转运蛋白（ANT）的生产，新型ANT配体及其筛选试验。
公开(公告)号：US06906175B2
公开(公告)日：2005-06-14
申请号：US09809889
申请日：2001-03-16
申请人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley , Scott W. Miller , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
发明人： Christen M. Anderson , Robert E. Davis , William Clevenger , Sandra Eileen Wiley , Scott W. Miller , Tomas R. Szabo , Soumitra S. Ghosh , Walter H. Moos , Yazhong Pei
IPC分类号： G01N33/50 , A61K31/704 , A61K31/7048 , A61K31/7056 , A61K31/7064 , A61K45/00 , A61P3/00 , A61P3/10 , A61P17/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/16 , A61P35/00 , A61P43/00 , C07H15/256 , C07H15/26 , C07K1/22 , C07K14/47 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/62 , C12P21/02 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566 , C07K1/00 , C07K14/00
CPC分类号： C07K14/47 , C07K2319/00 , C07K2319/07 , C07K2319/21 , C07K2319/23 , C12N15/62 , C12N2799/021
摘要： Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
摘要翻译：提供了用于产生腺嘌呤核苷酸转运蛋白（ANT）多肽和融合蛋白的组合物和方法，包括产生和使用具有调节启动子的重组表达构建体。还公开了ANT配体以及用于鉴定ANT配体的组合物和方法，结合ANT的试剂和与ANT相互作用的试剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式